Bupropion hydrochloride (Zyban): Stock issue

Supply issue Active

GlaxoSmithKline has advised that Zyban (bupropion hydrochloride) supply is currently being managed due to increased global demand and manufacturing constraints.


Stock continues to arrive in New Zealand on a regular basis which, at the moment, is monthly. GSK is managing stock to ensure it is distributed fairly, and to minimise any disruption for those using the treatment.  GSK is also aiming to increase its production volumes to cater for the new users, but due to lead times, this supply constraint may last until August 2022. 

Pharmacode: 2439743

Schedule listing(external link)

Alternative product

Varenicline (Champix) is unavailable due to manufacturing issue. Read the varenicline medicine notice

Nicotine patches, gum or lozenges are available and are fully funded to support people to stop smoking.

Schedule listing for nicotine products(external link)

Who to contact

If you have questions about supply of Zyban, please contact GSK:

If you have questions about funding, contact Pharmac: